Treatment needs and current options for postmenopausal osteoporosis
- 6 May 2016
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 17 (8) , 1141-1152
Abstract
Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised bone strength and increased risk of fractures, affecting up to 50% of postmenopausal women worldwide. Over the past 2 decades there have been consistent developments in the pharmacotherapy of osteoporosis with the availability of potent inhibitors of bone resorption (bisphosphonates, and denosumab) or stimulators of bone formation (PTH analogs) with substantial improvements over calcitonin or estrogen replacement. Areas covered: In this review we summarize the effects of existing treatment options for postmenopausal osteoporosis along with the unmet clinical needs and we discuss about the potential benefits of new compounds under development. Expert opinion: Despite the recent progresses, there are still limitations and unmeet needs with all the available drugs, mainly concerning treatment adherence, efficacy on the prevention of nonvertebral fractures and the long-term adverse events of antiresorptive regimens. Moreover, PTH analogs are the only available compounds able to stimulate bone formation, but with a restricted anabolic window of no more than 2 years. Of interest, the more recent advances in bone biology identified new targets for the development of drugs with a more potent and selective activity on either osteoclasts or osteoblasts, thus making possible to uncouple bone formation from bone resorption.Keywords
This publication has 97 references indexed in Scilit:
- Postmenopausal OsteoporosisNew England Journal of Medicine, 2016
- Osteoporosis: the evolution of a diagnosisJournal of Internal Medicine, 2015
- The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working GroupOsteoporosis International, 2014
- Osteocyte-Driven Bone RemodelingCalcified Tissue International, 2013
- Osteoporosis: now and the futureThe Lancet, 2011
- Bone remodelling: its local regulation and the emergence of bone fragilityBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Bone Quality — The Material and Structural Basis of Bone Strength and FragilityNew England Journal of Medicine, 2006
- Pathogenesis of osteoporosis: concepts, conflicts, and prospectsJournal of Clinical Investigation, 2005
- Sex Steroids and the Construction and Conservation of the Adult SkeletonEndocrine Reviews, 2002
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993